xwan on 02 April 2013
While encouraging, actual drug to market, probably still 10+ years away. We do have other anti-body targeted therapies already that is being used clinically, some with good results such as Gleevec (imatinib) for CML (now almost curable disease, remission rate 90%); we have other drugs that is not as good but prolong life for some patient such as breast cancer with HER2/NEU receptors, we use trazuzumab.
The new kid on the block is CD20 antagonist, Rituximab.
The CD receptor targeted therapy is probably the future of most cancer therapy.
